Journal article
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study
Future oncology (London, England), v 18(40), pp 4473-4482
01 Dec 2022
PMID: 36753353
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the phase III ARAMIS study. We evaluated outcomes in Black/African-American patients in ARAMIS.
Patients with nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide (n = 955) or placebo (n = 554) plus androgen-deprivation therapy. The primary end point was MFS. Secondary end points included OS and safety.
In 52 (3.4%) Black/African-American patients, darolutamide improved MFS (median: not reached vs 12.4 months) and OS (3-year survival rates: 100 vs 71%) versus placebo. The safety profile of darolutamide in Black/African-American patients was consistent with that of all ARAMIS patients.
In Black/African-American patients, darolutamide improved MFS and OS and was well tolerated, consistent with the overall ARAMIS population.
Metrics
Details
- Title
- Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study
- Creators
- Neal D Shore - Carolina Urologic Research CenterFelipe Cruz - Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo, 03102-002, BrazilLuke Nordquist - Urology Cancer Center, Omaha, NE 68130, USALaurence Belkoff - Urology AssociatesWilliam J Aronson - University of California, Los AngelesBhupendra Tolia - Eastchester Center for Cancer CareArnold Cinman - Tower Urology Medical GroupRoohollah Sharifi - Veteran's Administration, Chicago, IL 60612, USAJorge Ortiz - BayerJacqueline Parkin - BayerShankar Srinivasan - BayerToni Sarapohja - Orion CorporationMatthew R Smith - Massachusetts General Hospital
- Publication Details
- Future oncology (London, England), v 18(40), pp 4473-4482
- Grant note
- Bayer HealthCare
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:000928638400001
- Scopus ID
- 2-s2.0-85151045013
- Other Identifier
- 991021916798804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology